In a significant breakthrough for oncology, new findings from a global clinical trial reveal that a novel cancer jab can effectively eliminate tumours in patients with advanced cancers resistant to conventional therapies. The treatment, named amivantamab, has demonstrated remarkable efficacy, particularly in patients with head and neck cancers, and could reshape the landscape of cancer care.
Unprecedented Results in Tumour Response
The OrigAMI-4 trial, involving 102 participants across 11 countries, has yielded groundbreaking results. In a cohort of patients whose cancers had either metastasized or recurred following standard treatments, more than one third experienced substantial tumour reduction. Astonishingly, 15 individuals had their tumours completely eradicated within weeks of administration.
Professor Kevin Harrington, an expert in biological cancer therapies at the Institute of Cancer Research in London, highlighted the significance of these results, stating, “These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy.” This statement underscores the trial’s importance for a demographic with exceedingly limited treatment options.
Mechanism of Action and Treatment Administration
Amivantamab’s unique triple-action mechanism sets it apart from existing therapies. It simultaneously inhibits the epidermal growth factor receptor (EGFR) and the MET pathway, both of which are crucial for tumour growth and cancer cell survival. Additionally, it enhances the immune system’s ability to target and destroy cancer cells.
Unlike traditional cancer treatments that require intravenous administration, amivantamab is delivered via a small subcutaneous jab, significantly improving the patient experience. This method not only expedites the treatment but also allows for easier administration in outpatient settings. Patients typically receive the jab every three weeks, with side effects reported as mostly mild to moderate; fewer than 10% required treatment cessation due to adverse reactions.
Patient Experiences and Quality of Life
Among those who have benefited from this innovative treatment is Carl Walsh, a 56-year-old diagnosed with tongue cancer in May 2024. After initial treatments failed, he enrolled in the OrigAMI-4 trial in July 2025. Walsh shared his transformative journey, stating, “Before starting the trial, I struggled to speak properly and found eating difficult due to swelling and pain. Since beginning treatment, the swelling has reduced significantly, and my pain levels have improved considerably.”
The impact on Walsh’s life has been profound. He has resumed a normal diet and returned to work with no significant speech difficulties, a stark contrast to his condition prior to joining the trial. This personal account exemplifies the potential of amivantamab not just to prolong life, but to enhance the quality of life for cancer patients.
Implications for Future Cancer Treatments
The trial’s findings will be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting in Chicago, further amplifying the conversation around advanced cancer therapies. Researchers also noted that amivantamab has shown promising results in patients with lung cancer, indicating its broad applicability across various cancer types. Currently, the treatment is under investigation in approximately 60 clinical trials, targeting several malignancies including colorectal, brain, and gastric cancers.
The focus on head and neck cancers is particularly noteworthy, as the trial specifically excluded HPV-positive oropharyngeal squamous cell carcinoma patients. This distinction is crucial, given the notoriously challenging nature of head and neck cancers not linked to HPV, making the progress in this area vital.
Why it Matters
The emergence of amivantamab marks a pivotal development in cancer treatment, especially for patients with limited options after standard therapies fail. As highlighted by Professor Kristian Helin, Chief Executive of the Institute of Cancer Research, the study exemplifies the promise of rigorous cancer research in yielding meaningful advancements. The potential to achieve significant tumour response and improved survival outcomes in hard-to-treat populations represents a hopeful step forward in the ongoing battle against cancer. This breakthrough could not only enhance patient survival rates but also fundamentally change how oncologists approach treatment for aggressive cancers in the future.
